Skip to Main Content

Advertisement

Skip Nav Destination

Acute Leukemias

November 5, 2021

A collection of features and news articles published in ASH Clinical News related to acute leukemias

Keywords:

Sabatolimab Combined With Hypomethylating Agents Appears Safe and Effective in MDS and AML

Sabatolimab, an immunotherapeutic therapy targeting TIM-3 on immune and myeloid cells, was well-tolerated and led to durable clinical responses when combined with hypomethylating agents...

Azacitidine With Venetoclax and Magrolimab Shows Promise for Newly Diagnosed, High-Risk AML

A combination regimen consisting of azacitidine with venetoclax and magrolimab showed clinical activity in older and high-risk patients with newly diagnosed acute myeloid leukemia...

Multi-Omic Analysis Provides Insights into TP53-Mediated Evolution of Malignancies

A single-cell multi-omic analysis of the genetic, cellular, and molecular landscape of TP53-driven transformation can provide unique insights into the evolution of chronic hematologic...

Racial-Ethnic Disparities in Pediatric AML Vary Across Cytogenetic Subclasses

A recent study published in Blood Advances showed that cytogenic lesions in children with acute myeloid leukemia (AML) differ by race-ethnicity, with higher rates...

Evaluating a Machine Learning Approach for the Detection of AML

Researchers led by Jan-Niklas Eckardt, MD, of the Technical University Dresden in Germany, have developed a machine learning approach that allows for rapid and...

Routine Screening for Germline Variants in Patients With AML

Nearly 14% of adult patients with acute myeloid leukemia (AML) have pathogenic or likely pathogenic germline variants that make them susceptible to myeloid malignancies,...

Modified EASIX Score Predicts CRS and ICANS Before Severe Symptoms in Patients With B-Cell...

A modified version of the EASIX (Endothelial Activation and Stress Index) score, when calculated prior to and soon after chimeric antigen receptor (CAR) T-cell...

Advertisement

  CURRENT ISSUE
  Mid-January 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X